Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > fungal keratitis treatment market
Get a free sample of Fungal Keratitis Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Fungal Keratitis Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The fungal keratitis treatment industry is characterized by intense competition among key players striving to improve patient outcomes and address unmet medical needs in the management of this challenging eye condition. Some of the significant players Merck & Co. Inc., Pfizer, Inc., Glenmark Pharmaceuticals, and Alvogen are likely to hold significant market shares due to their extensive product portfolios and global reach.
Prominent players operating in the fungal keratitis treatment industry include:
Global fungal keratitis treatment market was valued at USD 875.4 million in 2023 and is anticipated to grow at 6.1% CAGR from 2024
The geriatric segment in the fungal keratitis treatment industry is anticipated to reach USD 711.2 million by 2032, due to age-related changes in the immune system, ocular surface, and underlying medical conditions such as diabetes and immunosuppression.
North America fugal keratitis treatment market was valued at USD 353.7 million in 2023 and is anticipated to reach USD 585.6 million by 2032, owing to advanced healthcare infrastructure, high prevalence of risk factors and stringent regulatory framework.
Alvogen , Aurolab , Bausch Health Companies Inc., Eyevance Pharmaceuticals LLC , Gilead Biosciences, Inc. , Glenmark Pharmaceuticals Ltd., Leadiant Biosciences, Inc., Merck & Co. Inc., Novo Holdings A/S (Xellia Pharmaceuticals) and Pfizer Inc.